In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest pays AZ $210mm for all rights to Novexel candidate

Executive Summary

Following its concurrently announced acquisition of antibiotics developer Novexel, AstraZeneca has agreed to hand over all rights for Novexel's lead broad-spectrum candidate NXL104 to Forest Laboratories for $210mm. The deal sees AZ both granting and receiving rights through what turns out to be a very complex transaction.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies